

Supplementary Materials

Novel phthalazin-1(2H)-one derivatives displaying a dithiocarbamate moiety as potential anticancer agents

Table of contents

Results and discussion

Table S1. CYP450 inhibition profile of compounds **6e**, **8e**, **6g**, **9a-b**, **9d** and **9g** 1

Table S2. Toxicity model profile of compounds **6e**, **8e**, **6g**, **9a-b**, **9d** and **9g** 2

Materials and Methods

Chemical synthesis

Synthesis of 2-(2-bromoethyl)phthalazinones **15-17** 2

¹H NMR and ¹³C NMR spectra of compounds **6-9** 3

Table S1. CYP450 inhibition predicted by SwissADME for compounds **6e**, **8e**, **6g**, **9a-b**, **9d**, and **9g**.

Compound	CYP1A2	CYP2C19	CYP2C9	CYP2D6	CYP3A4
6e	Yes	Yes	Yes	No	Yes
8e	Yes	Yes	Yes	No	Yes
6g	Yes	Yes	Yes	No	No
9a	Yes	Yes	Yes	No	Yes
9b	Yes	Yes	Yes	No	Yes
9d	Yes	Yes	Yes	No	Yes
9g	Yes	Yes	Yes	No	No

Table S2. Toxicity model predicted by ProTox-II for compounds **6e**, **8e**, **6g**, **9a-b**, **9d**, and **9g**.

Compound	Hepatotoxicity Probability	Carcinogenicity Probability	Immunotoxicity Probability	Mutagenicity Probability	Cytotoxicity Probability
6e	Inactive 0.56	Inactive 0.55	Inactive 0.80	Inactive 0.53	Inactive 0.67
8e	Inactive 0.58	Inactive 0.56	Inactive 0.98	Inactive 0.51	Inactive 0.67
6g	Inactive 0.54	Active 0.53	Inactive 0.84	Inactive 0.53	Inactive 0.72
9a	Inactive 0.57	Active 0.53	Inactive 0.98	Inactive 0.51	Inactive 0.71
9b	Inactive 0.58	Active 0.53	Inactive 0.99	Inactive 0.51	Inactive 0.71
9d	Inactive 0.58	Inactive 0.57	Inactive 0.93	Inactive 0.52	Inactive 0.6
9g	Inactive 0.55	Active 0.53	Inactive 0.92	Inactive 0.51	Inactive 0.72

Materials and Methods

Chemical synthesis

General procedure for the preparation of 2-(2-bromoethyl)phthalazin-1(2H)-ones (**15-17**)

To a solution of phthalazinone **12-14** (2 mmol) in DMF (20 mL) was added K₂CO₃ (8 mmol) and 1,2-dibromoethane (12 mmol). The reaction mixture was stirred at 60 °C for 1.5 h and the solvent was evaporated to dryness. The residue was purified by column chromatography on silica gel (hexane/EtOAc, 5:1) to afford the desired compound.


2-(2-Bromoethyl)phthalazin-1(2H)-one (15). White solid; yield: 50%; R_f = 0.4 (hexane/EtOAc, 1:1); ¹H NMR (CDCl₃): δ = 8.43 (d, 1H, *J* = 7.7 Hz, H8), 8.18 (s, 1H, H4), 7.85-7.76 (m, 2H, H6, H7), 7.71 (d, 1H, *J* = 7.3 Hz, H5), 4.63 (t, 2H, *J* = 6.8 Hz, H1'), 3.77 (t, 2H, *J* = 6.8 Hz, H2'); ¹³C NMR (CDCl₃): δ = 159.6 (C1), 138.3, 133.5, 132.0, 129.8, 127.9, 126.9 (C8), 126.3, 52.2 (C1'), 28.6 (C2'); HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₀H₁₀BrN₂O: 252.99710, found: 252.99790.

2-(2-Bromoethyl)-4-p-tolylphthalazin-1(2H)-one (16). White solid; yield: 75%; R_f = 0.4 (hexane/EtOAc, 1:1); ¹H NMR (CDCl₃): δ = 8.53 (d, 1H, *J* = 7.1 Hz, H8), 7.82-7.75 (m, 3H, H5,



H6, H7), 7.49 (d, 2H, $J = 7.9$ Hz, Ar), 7.34 (d, 2H, $J = 7.9$ Hz, Ar), 4.69 (t, 2H, $J = 7.0$ Hz, H1'), 3.80 (t, 2H, $J = 7.0$ Hz, H2'), 2.46 (s, 3H, CH₃); ¹³C NMR (CDCl₃): δ = 159.3 (C1), 147.7, 139.5, 133.1, 132.1, 131.6, 129.5, 129.4, 129.3, 128.2, 127.4, 127.0, 52.1 (C1'), 28.5 (C2'), 21.5 (CH₃); HRMS (ESI): m/z [M+H]⁺ calcd for C₁₇H₁₆BrN₂O: 343.04405, found: 343.04401.


2-(2-Bromoethyl)-4-methylphthalazin-1(2H)-one (**17**). White solid; yield: 45%; R_f = 0.4 (hexane/EtOAc, 1:1); ¹H NMR (CDCl₃): δ = 8.45-8.41 (m, 1H, H8), 7.83-7.72 (m, 3H, H5, H6, H7), 4.56 (t, 2H, $J = 7.0$ Hz, H1'), 3.73 (t, 2H, $J = 7.0$ Hz, H2'), 2.57 (s, 3H, CH₃); ¹³C NMR (CDCl₃): δ = 159.4 (C1), 144.1 (C4), 133.2, 131.5, 129.9, 127.7, 127.2, 125.0, 51.8 (C1'), 28.5 (C2'), 19.0 (CH₃); HRMS (ESI): m/z [M+H]⁺ calcd for C₁₁H₁₂BrN₂O: 267.01275, found: 267.01300.

¹H NMR and ¹³C NMR spectra of compounds 6-9






6a








6b






6c



















6d















6e






































































9g

